| Title | Imatinib mesylate (Gleevec™) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial. |
| Publication Type | Journal Article |
| Year of Publication | 2014 |
| Authors | Gordon J, Udeh U, Doobay K, Magro C, Wildman H, Davids M, Mersten JN, Huang W-T, Lyman S, Crow MK, Spiera RF |
| Journal | Clin Exp Rheumatol |
| Volume | 32 |
| Issue | 6 Suppl 86 |
| Pagination | S-189-93 |
| Date Published | 2014 Nov-Dec |
| ISSN | 0392-856X |
| Keywords | Adult, Antirheumatic Agents, Benzamides, Calcium Channel Blockers, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Hydroxychloroquine, Imatinib Mesylate, Lung Diseases, Interstitial, Male, Middle Aged, Piperazines, Prednisone, Protein Kinase Inhibitors, Proton Pump Inhibitors, Pyrimidines, Respiratory Function Tests, Scleroderma, Diffuse, Treatment Outcome |
| Abstract | OBJECTIVES: We aimed to assess the long-term safety and tolerability of imatinib in diffuse cutaneous systemic sclerosis (dcSSc). METHODS: In this open-label, single-arm, extension-phase clinical trial, patients continued imatinib for 24 months following 12 months of initial treatment. RESULTS: Seventeen patients were enrolled. Forty of 92 adverse events (AE) and 0/6 serious (S) AEs were possibly related to medication. The MRSS decreased from a median of 21 to 16, (p=0.002). CONCLUSIONS: This study demonstrates long-term safety and tolerability of imatinib in a substantial proportion of patients with dcSSc. This is important in evaluating the relevance of this therapy in a chronic disease such as SSc. |
| Alternate Journal | Clin Exp Rheumatol |
| PubMed ID | 25152211 |
Related Faculty:
Cynthia M. Magro, M.D.